Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Acquire TherImmune for $52 Million

NEW YORK, Feb. 25 - Gene Logic said today it has signed an agreement to acquire TherImmune Research, of Gaithersburg, Md., for $52 million in cash and stock.

 

TherImmune, founded in 1998, is a privately owned drug discovery, pre-clinical, and clinical trial contract research organization.

 

Under the agreement, Gene Logic will pay TherImmune shareholders $31 million in cash, and will issue them approximately 3.1 million new shares in a private placement, the value of which Gene Logic estimates at $21 million but says will be subject to the closing share price as of the date the transaction closes. The companies expect the acquisition to close during the second quarter of this year, subject to shareholder and regulatory approval.

   

Gene Logic said in a statement that the acquisition enables it to grow by creating its own outsourcing unit for drug discovery and development services in order to better address the needs of biopharma customers, and also to "drive genomic information into mainstream drug discovery and development," and enhance its revenue growth.

 

The combined company is to have a staff of 500 and be headquartered in Gaithersburg, Md. TherImmune president Stephen Trevisan will become a member of Gene Logic's senior management team, and will become a  member of Gene Logic's board of directors.                                

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.